Hormonal Therapy Market Size, Share, Growth and Forecast, 2025-2035

Aging populations and safer labels lift hormone replacement

The global hormonal therapy market was valued at USD 10.97 billion in 2025 and is projected to increase from USD 11.69 billion in 2026 to USD 20.71 billion by 2035, registering a CAGR of 6.56% during 2026–2035. Demand comes from women treated for menopause symptoms, adults and children with growth hormone deficiency, people with an underactive thyroid and men with low testosterone. North America held the largest regional share, 44.0% in 2025, because the U.S. combines high branded prices with wide insurance cover for endocrine care. Asia Pacific is the fastest-growing region at 7.82% a year, as aging populations in China, Japan and South Korea raise diagnosis and treatment rates. The main regulatory change came in November 2025, when the U.S. Food and Drug Administration began removing broad boxed warnings from menopausal hormone products.

Which hormone replacement medicines are counted?

The market counts manufacturer revenue from prescription medicines that replace or supplement hormones the body no longer makes in sufficient amounts. It covers estrogen and estrogen-progestogen products for menopause, recombinant growth hormone, thyroid hormone tablets and testosterone gels, patches, injections and pellets. Buyers include hospital pharmacies, retail pharmacies and drug stores, online pharmacies, insurers and patients paying out of pocket.

The scope excludes hormonal contraceptives, fertility hormones and hormone-blocking cancer medicines such as those used for breast and prostate tumors. Compounded bioidentical products, dietary supplements and diagnostic hormone tests are also left out, because they are not approved replacement medicines.

Estrogen products and oral tablets hold the most value

Why do estrogen products hold the largest share?

Based on therapy type, the market is categorized into estrogen and combinations replacement therapy, growth hormone replacement therapy, thyroid hormone replacement therapy and testosterone hormone replacement therapy. Estrogen & Combinations Replacement Therapy led with a 36.0% share of 2025 value, because menopause symptoms affect a very large group of women. Estrogen products also grow fastest at 7.06% a year, as easing U.S. label warnings bring women back to treatment.

How do menopause and deficiency states divide demand?

Based on indication, the market is categorized into menopause, hypothyroidism, male hypogonadism and growth hormone deficiency. Menopause led with a 37.0% share of 2025 value, because hot flashes, sleep problems and bone loss drive long courses of treatment. Menopause grows fastest at 7.06% a year, as clinicians revisit treatment for women within 10 years of menopause onset.

Why do oral tablets still lead hormone delivery?

Based on route of administration, the market is categorized into oral, transdermal and parenteral products. Oral products led with a 42.0% share of 2025 value, because thyroid tablets and many estrogen products are taken by mouth. Transdermal products grow fastest at 7.72% a year, as patches and gels avoid first-pass liver metabolism. This benefit matters most for women with clotting concerns and for men who prefer daily gels over injections.

Where do patients fill hormone prescriptions?

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and drug stores, and online pharmacies. Retail Pharmacies & Drug Stores led with a 50.0% share of 2025 value, because most patients refill long-term prescriptions close to home. Online Pharmacies grow fastest at 8.33% a year, as telehealth menopause and testosterone clinics ship refills.

Menopause care, testosterone relabeling and longer lives

How do easing menopause warnings revive demand?

Broad boxed warnings had discouraged many women and doctors from using menopausal hormone products for more than two decades. On Feb. 12, 2026, the FDA approved labeling changes for six menopausal hormone products that remove boxed warning statements on cardiovascular disease, breast cancer and probable dementia. The agency asked 29 companies to propose such changes after starting the process in November 2025. As a result, more women within 10 years of menopause are likely to start treatment, and some former users may return.

Why does a large untreated group matter?

The pool of women who could benefit from treatment is far larger than the number now receiving it. The FDA noted that about 41 million U.S. women were ages 45 to 64 in 2020, while only about 2 million women in a similar age range received a hormone prescription. This gap shows how much room remains for wider use among women in midlife. In turn, even small gains in treatment rates add large volumes for estrogen, progestogen and vaginal estrogen products.

Download Free Sample

How do testosterone label changes support use?

Clearer safety evidence is reshaping how doctors view testosterone treatment for men with low hormone levels. On Feb. 28, 2025, the FDA required class-wide labeling changes that added TRAVERSE trial results and removed cardiovascular risk language from the boxed warning on testosterone products. A new blood pressure warning was added where one was missing. Because the trial eased heart risk concerns, more urologists and endocrinologists are willing to prescribe testosterone injections and gels.

Why does population aging widen the patient pool?

Hormone deficiency becomes more common with age, so aging populations steadily raise the number of people who need replacement. The WHO expects people aged 60 and over to rise from 1 billion in 2020 to 1.4 billion by 2030, and to reach 2.1 billion by 2050. Older adults also face higher rates of thyroid disease and bone loss, which often require years of daily treatment. As a result, demand for thyroid, estrogen and testosterone products grows across both rich and middle-income countries.

Weekly growth hormone, patches and online prescribing

Why is weekly growth hormone on the rise?

Growth hormone treatment is shifting from daily injections toward once-weekly long-acting products. On July 28, 2025, Ascendis Pharma announced U.S. approval of once-weekly Skytrofa for adults with growth hormone deficiency, adding to its use in children aged 1 year and older. Fewer injections improve adherence among children and adults on lifelong treatment. This shift raises value per patient and pressures makers of daily products. In turn, payers weigh the higher price of weekly products against better adherence.

How are skin patches and gels gaining ground?

Transdermal patches and gels are gaining share because they deliver hormones through the skin rather than through the liver. Many menopause specialists prefer skin delivery for women with higher clotting or migraine risks. Wider use of transdermal delivery systems also supports testosterone gels for men. As a result, transdermal products grow faster than oral tablets through 2035. Because patches need steady adhesion and dose control, makers invest in thinner and smaller designs that patients tolerate for years.

Download Free Sample

Where is the opening in men's health?

Men with low testosterone offer a clear opening, because many have never been tested or treated. On June 18, 2026, HHS requested further class-wide updates to testosterone labels, including removal of the limitation of use for age-related low testosterone. The request would also narrow the prostate cancer contraindication to metastatic disease. If adopted, these changes could widen the group of men eligible for treatment. As a result, makers of gels, patches and injections could reach older men who were previously advised against therapy.

Can telehealth clinics open new prescribing channels?

Telehealth clinics for menopause and men's health create an opening, because they reach patients who avoid in-person visits. Online consultations followed by home delivery through online pharmacies shorten the path from symptoms to treatment. These services also handle repeat refills for thyroid and estrogen products. In turn, suppliers gain steady volume from patients who stay on treatment for years. However, regulators watch online prescribing closely, so clinics must follow labeling and monitoring rules.

Safety fears, non-hormone rivals and generic price pressure

How do lingering safety fears limit treatment?

Many women and doctors still remember the breast cancer and heart risk warnings that followed the Women's Health Initiative study two decades ago. These fears persist even after the FDA began removing boxed warnings in November 2025. Some primary care doctors lack training in menopause care and avoid prescribing. As a result, uptake depends on education campaigns and clear guidance from specialist societies. Because the first relabeled products only reached pharmacies in 2026, a full recovery in prescribing may take several years.

Why do non-hormone rivals threaten estrogen demand?

New non-hormone medicines give women an alternative for hot flashes, which may draw some patients away from estrogen. On Oct. 24, 2025, Bayer announced U.S. approval of Lynkuet, a hormone-free treatment for moderate to severe hot flashes. The medicine blocks two neurokinin receptors involved in temperature control. However, non-hormone options do not protect bone, so estrogen keeps a role for women at risk of postmenopausal osteoporosis. In turn, doctors may use both options for different patients.

How does generic pricing weigh on value?

Thyroid tablets and many estrogen and testosterone products are available as low-cost generics, which caps value growth. Generic levothyroxine and estradiol tablets sell for a small fraction of branded prices in most countries. As a result, rising patient numbers add less value than they would for branded medicines. Makers respond by focusing on new delivery forms and long-acting products that justify higher prices. This pattern is strongest in thyroid care, where most patients already take low-cost generic levothyroxine tablets.

What monitoring needs slow testosterone and growth hormone use?

Testosterone and growth hormone treatments require regular blood tests and dose checks, which adds cost and burden for patients. Testosterone products now carry blood pressure warnings, so doctors must monitor patients more closely. Growth hormone treatment for children involves years of specialist visits and growth tracking. These requirements slow uptake in regions where few endocrinologists practice. As a result, makers fund nurse programs and home testing to help patients stay on treatment.

North America leads while Asia Pacific grows fastest

North America leads on branded products and relabeling

North America held a 44.0% share of 2025 value and grows at 6.22% a year through 2035. The U.S. dominates spending, because branded estrogen, growth hormone and testosterone products carry high list prices and insurance covers most endocrine care. The removal of broad menopause warnings since November 2025 and testosterone label changes since February 2025 support more prescribing. However, generic thyroid and estradiol tablets hold value growth below the global rate.

Europe balances specialist care and price controls

Europe held a 27.0% share of 2025 value and grows at 5.92% a year, the slowest pace among the five regions. Germany, the U.K., France, Italy and Spain account for most demand, with strong use of transdermal estrogen patches and gels. National price controls and generic substitution keep value growth modest. However, wider menopause awareness campaigns in several countries lift the number of women on treatment. Specialist menopause clinics also help women choose between tablets, patches and gels.

Download Free Sample

Asia Pacific grows on aging and diagnosis

Asia Pacific held a 19.0% share of 2025 value and is the fastest-growing region at 7.82% a year. Japan, China and South Korea have some of the fastest-aging populations in the world, which raises thyroid, menopause and growth hormone demand. India adds large volumes through low-cost generic thyroid tablets sold in retail pharmacies. As incomes rise, more patients pay for branded long-acting growth hormone and transdermal products. In turn, local generic makers expand supply of estradiol and thyroid tablets.

Latin America relies on generics and private care

Latin America held a 6.0% share of 2025 value and grows at 7.12% a year through 2035. Brazil and Mexico account for most demand, with private clinics serving women seeking menopause treatment.

Gulf states lead a small regional base

The Middle East & Africa held a 4.0% share of 2025 value and grows at 7.22% a year. Gulf states lead spending on branded growth hormone and testosterone products, while most of Africa relies on generics.

Download Free Sample

Label changes, approvals and reviews since 2025

Long-acting injections and skin delivery reshape dosing

• Long-acting growth hormone products such as lonapegsomatropin are given once a week, which replaces daily injections for children and adults.
• Transdermal estradiol patches and gels deliver estrogen through the skin, which avoids first-pass liver metabolism.
• Low-dose vaginal estrogen treats local genitourinary symptoms with minimal absorption into the bloodstream.
• Testosterone gels and pellets offer steady hormone levels without frequent injections, which suits men on long-term treatment.
• Narrow-dose thyroid tablets such as levothyroxine sodium in fine dose steps let doctors adjust treatment precisely for each patient.

Diversified drugmakers and generic suppliers share the field

Competition in hormone replacement is shared between large diversified drugmakers with branded endocrine portfolios and generic suppliers of tablets, patches and gels. Pfizer Inc and Eli Lilly and Company hold established positions in estrogen and growth hormone products, while AbbVie Inc supplies widely used thyroid and testosterone brands. Bayer AG competes in women's health and added a hormone-free hot flash treatment in October 2025, which broadens its menopause offer. Novartis AG, Merck and Co Inc, Roche Holding AG and Amgen Inc hold endocrine and specialty portfolios that touch hormone care. Teva Pharmaceutical Industries Ltd and Viatris Inc supply low-cost generic estradiol, levothyroxine and testosterone products. Because generics dominate older molecules, branded makers compete on long-acting forms, skin delivery and support programs that help patients stay on treatment.

Companies profiled and their roles in this market

Regulatory relabeling, not new molecules, sets the pace

Credence Research's view is that regulatory relabeling, rather than new molecules, will set the growth pace in hormone replacement through 2035. The removal of broad menopause warnings and clearer testosterone safety data bring back patients who avoided treatment for years. Estrogen products keep the largest share, while weekly growth hormone and skin delivery raise value per patient. Generic pricing limits gains in thyroid care, and non-hormone rivals compete for hot flash patients. Companies with long-acting forms and telehealth partnerships are best placed.

How the 2025 baseline and forecast were built

The report uses 2025 as the base year and forecasts market value to 2035, with growth rates stated for 2026–2035. Market values come from the Credence Research market model, which combines treated patient numbers by indication, typical dosing, branded and generic price levels and channel mix by region. Splits by therapy type, indication, route of administration, distribution channel and region are Credence Research estimates. Sources used include FDA and HHS announcements, WHO population data and company announcements. No primary interviews or surveys were used to build the estimates in this report.

More treated women and men and simpler dosing by 2035

By 2035, the hormonal therapy market reaches USD 20.71 billion, with more women and men treated earlier and for longer. Estrogen and combination products remain the largest therapy type as menopause care returns to mainstream practice. Weekly growth hormone replaces most daily injections in high-income countries. Transdermal products and online pharmacies gain share as patients seek convenient options. Generic thyroid tablets keep volume high in Asia and Latin America, while branded makers focus on long-acting and skin-delivered products.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.